Exhibit 10.8.3


 


REPURCHASE AND FORFEITURE AGREEMENT


 


This REPURCHASE AND FORFEITURE AGREEMENT
(this “Agreement”) is made as of December [•], 2016, by and among (i) NeuroMetrix, Inc., a Delaware corporation
(the “Company”), (ii) the parties identified on Exhibit A hereto (the “Investors”).


 


WHEREAS, the Investors hold an aggregate
of 19,458.90 shares of the Company’s Series D Convertible Preferred Stock in the amounts identified on Exhibit A (the “Preferred
Stock”);


 


WHEREAS, the Investors are also the holders
of certain warrants that were issued between 2012 and 2016 to purchase an aggregate of 26,500,584 shares of Common Stock (the “Warrants”)
of the Company, par value $0.0001 per share (“Common Stock”), in the amounts and at the exercise price identified
on Exhibit A;


 


WHEREAS, the Company has filed a registration
statement on Form S-1 for the offer and sale of Class A units consisting of Common Stock and Warrants and Class B units consisting
of Series E Preferred Stock and warrants to purchase Common Stock of the Company (the “Offering”);


 


WHEREAS, the Investors have indicated
an interest in purchasing Class B units in the Offering, provided that the Company repurchases the Preferred Stock in connection
with the closing of the Offering; and


 


WHEREAS, in connection with the closing
of the Offering, the Company desires to repurchase from the Investors, and the Investors desire to sell to the Company, the Preferred
Stock (the “Repurchased Shares”) for an aggregate agreed upon purchase price of $19,458,900.00 (the “Repurchase
Price”) and, in connection with such transaction, the Investors have agreed to forfeit the Warrants identified on Exhibit
A.


 


NOW, THEREFORE, in consideration of the
mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereby agree as follows:


 


		1.	Repurchase of the Preferred Stock and Forfeiture of Warrants.



 


(a) At the closing of the Offering, the
Company hereby agrees to repurchase from the Investors, and the Investors hereby agree to sell, transfer and assign to the Company,
free and clear of any and all Encumbrances (as defined below), the Repurchased Shares at a price per share equal to $1,000.00,
and for an aggregate purchase price equal to the Repurchase Price. In addition, the Company and the Investors hereby acknowledge
that, on the date hereof, the Investors have forfeited the Warrants identified on Exhibit A under the caption “Securities
Repurchased and Forfeited in the Transaction”, which shall be null and void upon the closing of the Offering. The repurchase
of the Preferred Stock and the related forfeiture of the Warrants are collectively referred to herein as the “Transaction”.
The Transaction shall have no effect on the remaining Warrants or on any other securities of the Company held by the Investors,
which shall remain outstanding.


 




     


     


    

 


(b) On or prior to the Closing (as defined
below), each Investor hereby agrees to deliver to the Company:


 


(i) the certificate representing all of the Repurchased
Shares;


 


(ii) a duly executed stock assignment in the form attached
hereto as Exhibit B-1 and B-2, as applicable; and


 


(iii) certificate(s) representing Warrants to purchase
26,500,584 shares of Common Stock.


 


(c) Upon payment of the Repurchase Price,
the Preferred Stock shall cease to be outstanding for any and all purposes, and the Investors shall no longer have any rights as
a holder of the Preferred Stock.


 


(d) The closing of the Transaction (the
“Closing”) shall take place at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., on the same
date and simultaneously with the closing of the Offering.


 


2. Representations and Warranties
of Investors. Each Investor hereby represents and warrants to the Company as follows:


 


(a) Ownership. All of the Repurchased
Shares and Warrants are owned of record and beneficially by each Investor, and each Investor has good and marketable title to the
Repurchased Shares, free and clear of any security interest, claims, liens, pledges, options, encumbrances, charges, agreements,
voting trusts, proxies or other arrangements or restrictions whatsoever (collectively, “Encumbrances”), except
for such legend and related transfer restrictions as are required under the Securities Act of 1933, as amended. As of the date
hereof, each Investor will deliver to the Company good and marketable title to the Repurchased Shares, free and clear of any Encumbrances.


 


(b) Legal Capacity. Each Investor
has full legal capacity to enter into and perform its obligations set forth in this Agreement. This Agreement, when executed and
delivered by each Investor, will constitute the valid and legally binding obligation of the Investor, enforceable in accordance
with its terms (except as enforceability may be limited by principles of public policy, applicable bankruptcy, insolvency, reorganization,
moratorium, fraudulent conveyance or other similar laws affecting the enforcement of creditors’ rights and remedies generally
or general principles of equity (regardless of whether considered and applied in a proceeding at law or in equity)).


 


(c) Conflicts. The execution, delivery
and performance of this Agreement by each Investor does not, and will not, conflict with or result in a breach of any agreement,
instrument, order, judgment, decree, law or governmental regulation to which Investor or the Repurchased Shares are subject.


 


(d) Acknowledgment. Each Investor
believes that it has received all the information it considers necessary or appropriate for deciding whether to sell the Preferred
Stock to the Company pursuant to this Agreement. Each Investor has not been induced to agree to and execute this Agreement by any
statement, act or representation of any kind or character by anyone, except as contained herein. Each Investor further represents
that such Investor has fully reviewed this Agreement and has full knowledge of its terms, and executes this Agreement of his or
her own choice and free will, after having received (or been given the opportunity to receive) the advice of his or her attorney(s).


 




     


     


    

 


		3.	Miscellaneous.



 


(a) All representations and warranties
contained herein or made in writing by any party in connection herewith will survive the execution and delivery of this Agreement
and the closing of the transactions contemplated hereby, regardless of any investigation made by the Company or on its behalf.


 


(b) This Agreement shall be governed by
and construed in accordance with the internal laws of the State of New York, without giving any effect to any choice of law or
conflict of law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the application
of the laws of any jurisdiction other than the State of New York.


 


(c) This Agreement may be executed in
one or more counterparts (including signature pages by means of facsimile, emailed .pdf file or other similar form of electronic
transmission), all of which taken together shall constitute one and the same instrument.


 


(d) This Agreement contains the entire
agreement and understanding among the parties with respect to the subject matter hereof and supersedes all prior agreements and
understandings, whether written or oral, relating to such subject matter in any way.


 


* * * * *


 




     


     


    

 


Signature Page to Repurchase and Forfeiture
Agreement 


 


IN WITNESS WHEREOF, the parties hereto
have executed this Repurchase Agreement on the date first written above.


 


	 	NEUROMETRIX, INC.
	 	 
	 	By:	 
	 	Name: Thomas T. Higgins
	 	Title: Chief Financial Officer
	 	 
	 	SABBY VOLATILITY WARRANT MASTER FUND, LTD.
	 	 
	 	By:	 
	 	Name:  Robert Grundstein
	 	Title:  COO of Investment Manager
	 	 
	 	SABBY HEALTHCARE MASTER FUND, LTD.
	 	 
	 	By:	 
	 	Name: Robert Grundstein
	 	Title:  COO of Investment Manager




 




     


     


    

 


Exhibit A


Investors


 


Securities Repurchased and Forfeited
in Transaction


 


	Holder	Series D Preferred

Stock

(to be repurchased)	Warrants to Purchase Common Stock

(to be forfeited)
	Sabby Volatility Warrant Master Fund, Ltd.	5,937.25	5,214 shares, Exercise Price $27.60, Original Issue Date February 13, 2012
	 	 	 
	 	 	58,501 shares, Exercise Price $8.00, Original Issue Date June 10, 2013
	 	 	 
	 	 	269,983 shares, Exercise Price $8.16, Original Issue Date June 26, 2014
	 	 	 
	 	 	1,138,500 shares, Exercise Price $5.00, Original Issue Date May 29, 2015
	 	 	 
	 	 	3,521,568 shares, Exercise Price $2.30, Original Issue Date December 31, 2015
	 	 	 
	 	 	3,839,335 shares, Exercise Price: $1.69, Original Issue Date: June 8, 2016
	Sabby Healthcare Master Fund, Ltd.	13,521.65	205,831 shares, Exercise Price $8.00, Original Issue Date June 10, 2013
	 	 	 
	 	 	317,473 shares, Exercise Price $8.16, Original Issue Date June 26, 2014
	 	 	 
	 	 	1,881,000 shares, Exercise Price $5.00, Original Issue Date May 29, 2015
	 	 	 
	 	 	7,301,960 shares, Exercise Price $2.30, Original Issue Date December 31, 2015
	 	 	 
	 	 	7,961,219 shares, Exercise Price: $1.69, Original Issue Date: June 8, 2016
	Total:	19,458.90	26,500,584


 




     


     


    

 


Exhibit B-1 


 


ASSIGNMENT SEPARATE FROM CERTIFICATE


 


FOR VALUE RECEIVED, Sabby Volatility Warrant
Master Fund, Ltd. (“Investor”) does hereby sell, assign and transfer unto NeuroMetrix, Inc., a Delaware corporation
(the “Company”), 6,930* shares of Series D Preferred Stock, $0.001 par value per share, of the Company, standing
in the undersigned’s name on the books of the Company represented by Stock Certificate No(s) PD0001 provided herewith and
does hereby irrevocably constitute and appoint each officer of the Company (acting alone or with one or more other such officers)
as attorney-in-fact to transfer the said securities on the books of the Company with full power of substitution in the premises.


 


	 	Sabby Volatility Warrant Master Fund, Ltd.
	Dated: ____________, 2016	 
	 	 	 
	 	Name:
	 	Title:


 


	In Presence of	 
	 	 
	 	 
	Witness	 


 


*The stock certificate included with this Assignment has a face
value of 6,930 shares of Series D Preferred Stock, but the Investor has previously converted 992.75 shares of Series D Preferred
Stock into Common Stock of the Company.


 




     


     


    

 


Exhibit B-2 


 


ASSIGNMENT SEPARATE FROM CERTIFICATE


 


FOR VALUE RECEIVED, Sabby Healthcare Master
Fund, Ltd. (“Investor”) does hereby sell, assign and transfer unto NeuroMetrix, Inc., a Delaware corporation
(the “Company”), 14,370* shares of Series D Preferred Stock, $0.001 par value per share, of the Company, standing
in the undersigned’s name on the books of the Company represented by Stock Certificate No(s) PD0002 provided herewith and
does hereby irrevocably constitute and appoint each officer of the Company (acting alone or with one or more other such officers)
as attorney-in-fact to transfer the said securities on the books of the Company with full power of substitution in the premises.


 


	 	Sabby Healthcare Master Fund, Ltd.
	Dated: ____________, 2016	 
	 	 	 
	 	Name: 
	 	Title:


 


	In Presence of	 
	 	 
	 	 
	Witness	 


 


*The stock certificate included with this Assignment has a face
value of 14,370 shares of Series D Preferred Stock, but the Investor has previously converted 848.35 shares of Series D Preferred
Stock into Common Stock of the Company.